Real Life Lipid Management in Hospitals Not Participating in PENELOPE Trial - Control Population for PENELOPE
Launched by CLINICAL OPERATIONS WCN B.V. · Dec 12, 2022
Trial Information
Current as of January 14, 2025
Completed
Keywords
ClinConnect Summary
The recent PENELOPE study was designed to determine the effect of a protocolized, Dutch-, and ESC- guideline based strategy of stepwise intensified lipid management in patients at very high risk for ACS. In PENELOPE 22 Dutch non-academic hospitals, members of the WCN investigator network, implemented a protocol guided guideline approach in a consecutive cohort of very high-risk patients admitted for ACS over the period 01-01-2019 to 31-08-2020. Lipid values and medication strategy are collected at baseline (index ACS), and after three months and one year post ACS, in order to establish the ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18 and ≤70 years
- • Alive at hospital discharge after admission for (N)STEMI between 1-1-2019 and 31-08-2020
- • Planned for follow-up at a participating PENELOPE CTRL site
- * History of T2DM and/or history of ASCVD defined as either one of:
- • cerebrovascular disease/ event: transient ischemic attack, cerebral infarction, amaurosis fugax, retinal infarction
- • Coronary artery disease/ event: unstable angina pectoris, MI, ACS, coronary revascularization (coronary angioplasty or surgical procedure for coronary bypass)
- • Peripheral artery disease (symptomatic and documented obstruction of a distal extremity artery or surgical intervention (percutaneous transluminal angioplasty, bypass or amputation)
- Exclusion Criteria:
- • Pregnant and lactating women
- • Participation in lipid modifying drug trials up to two years after index cardiovascular event
Trial Officials
Marco Alings
Principal Investigator
WCN
About Clinical Operations Wcn B.V.
Clinical Operations WCN B.V. is a dedicated clinical trial sponsor specializing in the management and execution of clinical research across various therapeutic areas. With a commitment to advancing medical knowledge and improving patient outcomes, WCN B.V. employs a team of experienced professionals who leverage innovative methodologies and robust operational frameworks to ensure the successful execution of clinical studies. The organization is focused on fostering collaboration with research institutions and healthcare providers, aiming to streamline processes and enhance the efficiency of clinical trials while adhering to the highest regulatory standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Veldhoven, , Netherlands
Delft, , Netherlands
Den Haag, , Netherlands
Utrecht, , Netherlands
Deventer, , Netherlands
Helmond, , Netherlands
Leiden, , Netherlands
Den Haag, , Netherlands
Emmen, , Netherlands
Alkmaar, , Netherlands
Hardenberg, , Netherlands
Meppel, , Netherlands
Nijmegen, , Netherlands
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials